Pharmaceutical Executive-06-01-2015

 Specialty drug sales, record-breaking M&A paired with tax synergies, and global expansion helped to bring a new face into this year’s Pharma 50 top 10, and substantially boosted the rankings of several others.    

Masters of the deal converge in New York to discuss the status of their trade and the forces propelling M&A, licensing, and partnerships in the life sciences for 2015.

Institutionalizing the teachable moment with GENiE, and new network focused on advancing the idea that for healthcare to change, the education of its leaders must change first.

What you should know about integrated delivery networks.

What can companies do for an encore when their own blockbuster product is threatened by branded or generic competitors?

Pharma’s image is still suffering despite a rise in medical innovation. Dan Bobear offers five patient-centered strategies that could help in finally mending the gap.

Bryan Spielman outlines why China is poised for a data renaissance-one that could play a pivotal role in the next wave of pharma innovation.

New proposals from Congress to spur innovation will strain resources needed for regulatory approval.

The World Medical Innovation Forum unveils its inaugural list of breakthrough neuroscience technologies. We highlight a few here.

With the perception of Morocco as just a local healthcare market waning, the country is focused on forging partnerships with other african nations and developing its pharma industrial base and export capabilities.

Following the Conservatives surprise majority win in the UK election, Leela Barham asks what does it mean for pharma?